



REPUBLIC OF TURKEY
MINISTRY OF HEALTH
TURKISH MEDICINES AND MEDICAL DEVICES AGENCY
Certificate of a Pharmaceutical Product¹

This certificate conforms to the format recommended by the World Health Organization
(General instructions and explanatory notes attached)

Date: 15.12.2020

Certificate No : 2020/3681

Exporting Country : TURKEY

Importing Country : IRAQ

1. Name and dosage form of product : **Misintu 20 mg Powder For Solution For Injection/Infusion**

1.1. Active ingredient(s)² and amount(s) per unit dose⁻³ :
Mitomycin 20 mg

For complete qualitative composition including excipients, see attached.⁴

1.2. Is this product licensed to be placed on the market for use in the exporting country?⁵ yes/no (key in as appropriate) : **Yes**

1.3. Is this product actually on the market in the exporting country? Yes/no/unknown (key in as appropriate):
Yes

If the answer to 1.2. is yes, continue with section 2A and omit section 2B.

If the answer to 1.2. is no, omit section 2A and continue with section 2B.⁶

2A.1. Number of product licence⁷ and date of issue :
2019/480 - 01.10.2019

2A.2. Product-licence holder (name and address) :
**Koşel İlaç Sanayi ve Tic. A.Ş.
Koşuyolu Cad No:34, 34718 Koşuyolu
Kadıköy, İstanbul, TURKEY**

2A.3. Status of product-licence holder⁻⁸ a/b/c (key in appropriate category as defined in note 8)
c

2A3.1. For categories b and c the name and address of the manufacturer producing the dosage form are⁻⁹
(Key in appropriate category as defined in note 8)
**Onko İlaç Sanayi ve Ticaret A.Ş.
Gebze Organize Sanayi Bölgesi, 1700 Sokak, No:1703
Gebze, Kocaeli - TURKEY**

2A.4. Is Summary Basis of Approval appended?¹⁰ yes/no (key in as appropriate): **No**

2A.5. Is the attached, officially approved product information complete and consonant with the licence?¹¹ yes/no/not provided (key in as appropriate): **NOT PROVIDED**

2A.6. Applicant for certificate, if different from licence holder (name and address)⁻¹² _____

2B.1. Applicant for certificate (name and address) : _____

2B.2. Status of applicant : a/b/c (key in appropriate category as defined in note 8)

2B.2.1. For categories b and c the name and address of the manufacturer producing the dosage form are⁻⁹

2B.3. Why is marketing authorization lacking?
Not required/not requested/under consideration/refused (key in as appropriate)

2B.4. Remarks⁻¹³

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? yes/no/not applicable¹⁴ (key in as appropriate) : **Yes**
If no or not applicable proceed to question 4.

3.1. Periodicity of routine inspections (years) :
In every 3 years.

3.2. Has the manufacture of this type of dosage form been inspected? yes/no (key in as appropriate) : **Yes**

3.3. Do the facilities and operations conform to GMP as recommended by the World Health Organization¹⁵ yes/no/not applicable¹⁴ (key in as appropriate) : **Yes**

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?¹⁶ yes/no (key in as appropriate): **Yes**

If no, explain : _____

This certificate is valid until 15.12.2022
Address and certifying authority:

REPUBLIC OF TURKEY
MINISTRY OF HEALTH
TURKISH MEDICINES AND MEDICAL DEVICES AGENCY
SÖĞÜTÖZÜ MAH. 2176 SOK. NO:5 ÇANKAYA/ANKARA
FAX: (0312) 218 30 03 PHONE: (0312) 218 30 00

Name of authorized person

F. Handan ÖZTUNCA Pharm.M.Sc.
Head of Herbal and Supportive
Medicines Department



General instructions

Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

Explanatory notes

1. This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
2. Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.
3. The formula (complete composition) of the dosage form should be given on the certificate or be appended.
4. Details of quantitative composition are preferred but their provision is subject to the agreement of the product-licence holder.
5. When applicable, append details of any restriction applied to the sale, distribution or administration of the product that is specified in the product licence.
6. Sections 2A and 2B are mutually exclusive.
7. Indicate, when applicable, if the licence is provisional, or the product has not yet been approved.
8. Specify whether the person responsible for placing the product on the market:
 - (a) manufactures the dosage form;
 - (b) packages and/or labels a dosage form manufactured by an independent company; or
 - (c) is involved in none of the above.
9. This information can only be provided with the consent of the product-licence holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product licence. If the production site is changed, the licence has to be updated or it is no longer valid.
10. This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.
11. This refers to product information approved by the competent national regulatory authority, such as Summary Product Characteristics (SPC)
12. In this circumstance, permission for issuing the certificate is required from the product-licence holder. This permission has to be provided to the authority by the applicant.
13. Please indicate the reason that the applicant has provided for not requesting registration.
 - (a) the product has been developed exclusively for the treatment of conditions — particularly tropical diseases — not endemic in the country of export;
 - (b) the product has been reformulated with a view to improving its stability under tropical conditions;
 - (c) the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import;
 - (d) the product has been reformulated to meet a different maximum dosage limit for an active ingredient;
 - (e) any other reason, please specify.
14. Not applicable means the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.
15. The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series No. 823, 1992, Annex 1. Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).
16. This section is to be completed when the product-licence holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.

Misintu 20 mg Powder For Solution For Injection/Infusion

Module 3 Quality
Module 3.2.P Drug Product

KOÇSEL İLAÇ SANAYİ VE
TİCARET A.Ş.

3.2.P.1.2 Qualitative and Quantitative Composition of the Product (Misintu 20 mg Powder For Solution For Injection/Infusion)

Unit formula of the finished product named Misintu 20 mg Powder For Solution For Injection/Infusion is given in the **Table 1**.

Table 1. Unit formula

Raw Materials Name	Raw Materials Quantity (mg/vial)	Raw Materials Quantity (%) (w /w)	Function	Reference
Mitomycin	20	25.7	Active ingredient	Current European Pharmacopoeia
Mannitol	40	51.4	Volume filler	Current European Pharmacopoeia
2-Propanol*	0.75 ml	-	Solvent	Current European Pharmacopoeia
Tert-butanol*	0.75 ml	-	Solvent	Current European Pharmacopoeia
Water for Injection*	q.s. (8 ml)	q.s. (100 g)	Solvent	Current European Pharmacopoeia
Nitrogen gas	q.s.	q.s.	Inert gas/Stabilizer	Current European Pharmacopoeia

* Not available on finished product
q.s.: quantity of sufficient


İlaç Sanayi ve Ticaret A.Ş.
Koşuyolu Cad. No: 37 10740 Kadıköy-İST.
(0216) 544 90 00
Kadıköy V.D.: 974 001 0004
Hatice SAYGI
International Regulatory Affairs Manager